AU2018323528B2 - Indene derivatives and uses thereof - Google Patents
Indene derivatives and uses thereof Download PDFInfo
- Publication number
- AU2018323528B2 AU2018323528B2 AU2018323528A AU2018323528A AU2018323528B2 AU 2018323528 B2 AU2018323528 B2 AU 2018323528B2 AU 2018323528 A AU2018323528 A AU 2018323528A AU 2018323528 A AU2018323528 A AU 2018323528A AU 2018323528 B2 AU2018323528 B2 AU 2018323528B2
- Authority
- AU
- Australia
- Prior art keywords
- compound according
- pharmaceutically acceptable
- acceptable salt
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000003454 indenyl group Chemical class C1(C=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 119
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 201000011510 cancer Diseases 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 239000003937 drug carrier Substances 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000003207 proteasome inhibitor Substances 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 12
- 208000034578 Multiple myelomas Diseases 0.000 claims description 11
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 9
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- RMIODHQZRUFFFF-UHFFFAOYSA-M methoxyacetate Chemical compound COCC([O-])=O RMIODHQZRUFFFF-UHFFFAOYSA-M 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 22
- OWYMWLCFHDHVAH-UKTHLTGXSA-N (1E)-1-nonylidene-3-(trifluoromethyl)indene-5,6-diol Chemical compound FC(C1=C\C(\C2=CC(=C(C=C12)O)O)=C/CCCCCCCC)(F)F OWYMWLCFHDHVAH-UKTHLTGXSA-N 0.000 description 20
- -1 -C(0)-alkoxy Chemical group 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 108020003519 protein disulfide isomerase Proteins 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 229940079156 Proteasome inhibitor Drugs 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 7
- 229960005184 panobinostat Drugs 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000220479 Acacia Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000003964 Histone deacetylase Human genes 0.000 description 3
- 108090000353 Histone deacetylase Proteins 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- VKCYHJWLYTUGCC-UHFFFAOYSA-N nonan-2-one Chemical compound CCCCCCCC(C)=O VKCYHJWLYTUGCC-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical class C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 101000632319 Homo sapiens Septin-7 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000694408 Isomeris Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100027981 Septin-7 Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 150000002469 indenes Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 102200082402 rs751610198 Human genes 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940127020 second-generation proteasome inhibitor Drugs 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/38—Halogenated derivatives with at least one hydroxy group on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/42—Halogenated derivatives containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/16—Unsaturated compounds
- C07C61/28—Unsaturated compounds polycyclic
- C07C61/29—Unsaturated compounds polycyclic having a carboxyl group bound to a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/708—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/708—Ethers
- C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/52—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Abstract
The present invention relates to compounds of formula (I) :, including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.
Description
INDENE DERIVATIVES AND USES THEREOF
FIELD OF THE INVENTION
The invention relates generally to indene derivatives useful for the treatment of cancers and for reducing resistance to standard of care cancer therapy. All documents cited to or relied upon below are expressly incorporated herein by reference,
STATEM ENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
This invention was made with Government support under P20GM103542, UL1TR0O145Q, and R41 CA213488. The Government has certain rights in the invention.
BACKGROUND OF THE INVENTION
Proteasome inhibitors (Pis) such as, for example, bortezoroib, and histone deacetylase (HDAC) i nhibi tors such as, for example, panobinostat, are cornerstone agents in the treatment of multiple myeloma ( MM). Acquired or inherent resistance to these agents represents a significant obstacle to sustained and durable responses in patients, A need exists in the art for new, targeted strategies that target and kill MM and other cancer cell types, as well as enhance the activity of other therapies in resistant cancer cells.
SUMMARY OF THE INVENTION
The present invention is directed to a compound of formula (I):
(I),
- I -
wherein: i and 1¾, independently of each other, are hydrogen, hydroxy], aikyi, alkoxy, methoxy-acetate, phosphate, valine, Gly-Ser, ~OC(0)CH2QC(0)C¾, -OC(0)CH2OCH3, -OCH2C(0)C(CH3)3, - Ο0¾0(Ο)Ν¾ or -OCH2C(0)OH; or Rj and Ri; together with the carbon atoms to which they are aitached, form a 5 to 6-membered ring with one or two ring carbons replaced independently by oxygen or nitrogen;
R.3 is hydrogen, hydroxyl, halogen, cyano, -COOH, ~C(0)N¾, ~C(0)CH2CH3, -C(0)-alkoxy, alkyl, alkoxy, halo-lower alkyl, carboxyl, amide, ester or nitrile; and
R4 is alky! or alkenyl, said a!ky! or alkenyl optionall mono or bi-substituted independently with hydrogen, halogen, hydroxyl, -OCHrphenyl. cycloalkyl, -OCHj-halophenyl or™QC¾- phenylhaloalkyl, or a pharmaceutically acceptable salt thereof.
The present invention is also directed to a pharmaceutical composition, comprising a
therapeutically effective amount of a compound according to formula (1), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The present invention is further directed to a method for the treatment of cancer and enhancing the activity of standard of care cancer agents, exemplified here for therapy of multiple myeloma, and for reducing resistance to Pis, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to formula (I), or a
pharmaceutically acceptable salt thereof! and a pharmaceutically acceptable carrier.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 provides data showing Proteasome Inhibitor re-sensitizing characteristics of compounds of the in vention in resistant MM cells and various other cancer cell types.
Figure 2 shows single agent anti-tumor potency of compounds of the invention in a panel of solid and hematological cancer cell lines.
Figure 3 provides data showing HDACi re-sensitizing characteristics of compounds of the invention m panels of solid and hematological cancer eel! types.
Figure 4 shows inhibition of PDI activity by E64FC26 and E64.FC29 as measured by insulin aggregation.
Figure S shows activity data of representative compounds of the invention.
DETAILED DESCRIPTION OF THE INVENTION
It is to be understood that the descriptions of the present inveniion have been simplified to illustrate elements that are relevant for a clear understanding of the present inveniion, while eliminating, for the purpose of clarity, many other elements found in typical pharmaceutical compositions. Those of ordinary skill, in the art will recognize that other elements and/or steps are desirable and/or required in implementing the present invention. However, because such elements and steps are well known in the art, and because they do not facilitate a better understanding of the present invention, a discussion of such elements and steps is not provided herein. The disclosure herein is directed to all such variations and modifications to such elements and methods known to those skilled in the art. Furthermore, the embodiments identified and illustrated herein are for exemplary purposes only, and are not meant to be exclusive or limited i their description of the present invention.
The invention is directed to, for example, compounds that, inhibit protein disulfide isomerase (PDI), The compounds of the invention demonstrate anti -tumor efficacy as single agents and enhance the activity of other targeted cancer therapeutics, including proteasome and HDAC inhibitors.
The inventors identified PDI as a promising target in cancer, Including treatment resistant For example, the inventors identified compounds E64FC26;
Technical and scientific terms used herein have the meaning commonly understood by one of skill in the art to which the present invention pertains, unless otherwise defined. Reference is made herein to various methodologies and materials known to those of skill in the art. Standard reference works setting forth the general principles of pharmacology include Goodman and Oilman's The Pharmacological Basis of Therapeutics, JO* Ed., McGraw Hill Companies Inc., New York (2001 ), Any suitable materials and/or methods known to those of skill can be utilized in carrying out the present invention. However, preferred materials and methods are described. Materials, reagents and the like to which reference are made in the following description and examples are obtainable from commercial sources, unless otherwise noted.
A compound according to the invention is inherently intended to comprise all stereoehemically isomeric forms thereo The term "stereoehemically isomeric forms" as used hereinbefore or hereinafter defines ail the possibl stereoisomerie forms which the compounds of formula (I) and their -oxides, pharmaceutically acceptable salts or physiologically functional derivatives may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds
denotes the mixture of all possible stereochernically isomeric forms, In particular, stereogenie centers may have the R- or S-configuration; subsiituents on bivalent cyclic (partially) saturated radicals may have either the els- or trans-configuration. Compounds encompassing double bonds can have an E (entgegen) or Z (zusamraen)-stereochemistry at said double bond. The terms cis, trans, R, 5, E and Z are well known to a person skilled in the art
Stereochemicaily isomeric forms of the compounds of formula (I) are obviously intended to be embraced within the scope of this invention. Of special interest are those compounds of formula (I) which are stereochemicaily pure.
Following CAS-ttomenciature conventions, whe two stereogenie centers of known absolute configuration are present in a molecule, an R or S descriptor is assigned (based on Cahn-Ingold- Prelog sequence rule) to the lowest-numbered chiral center, the reference center. The
configuration of the second stereogenie center is indicated using relative descriptors [R*,R*] or [R*,S*j, where R* is always specified as the reference center and [R*,R*] indicates centers with the same ehirality and [R*,S*] indicates centers of unlike chirality. For example, if the lowest- numbered chiral center in the molecule has an S configuration and the second center is R, the stereo descriptor would be specified as S— R*,S*|. If "a" and "β" are used; the position of the highest priority substituent on the asymmetric carbon atom in the ring system having the lowest ring number, is arbitrarily always in the "a" position of the mean plane determined by the ring system. The position of the highest priority substituent on the other asymmetric carbon atom in the ring system relative to the position of the highest priority substituent on the reference atom is denominated "a", if it. is on the same side of the mean plane determined by the ring system, or "β", if it is on the other side of the mean plane determined by the ring system.
When a specific stereoisomerie form is indicated, this means that said form is substantially free, i.e. associated with less than 50%. preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, further preferably less than 2% and most preferably less than 1 % of the other isomeris). Thus, when a compound of formula (I) is for instance specified as (R,S), this means that the compound is substantially free of the (S,R) isomer.
The compounds of formula (I) may be synthesized in the form of mixtures, in particular raeemic mixtures, of enantiomers which can be separated from one another following art-known resolution procedures. The raeemic compounds of formula (I) may be converted into the corresponding diastereorneric salt forms by reaction with a suitable chiral acid. Said
diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid
chromatography using a chiral stationary phase. Said pure stereochemical ly isomeric forms may also be derived from the corresponding pure stereochemicaHy isomeric forms of the appropriate starting .materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
The tautomeric forms of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein e.g. an enol group is con verted in to a keto group (keto-enol tautomerism). Fautomeric forms of the compounds of formula (J) or of intermediates of the present invention are intended to be embraced bv the ambit of this invention.
The term "alky!" as used herein denotes an unbranched or branched chain, saturated, monovalent hydrocarbon residue containing 1 to 20 carbon atoms. In one embodiment, the number of carbon atoms in the alkyi chain can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms. In another embodiment, the number of carbon atoms in the alkyl chain can be from 5 to 16 and referred to as "(Cs-Cjfi.Ja kyl.*' The term "lower alkyl" denotes a straight or branched chairs hydrocarbon residue containing 1 to 6 carbon atoms. "Cj-ao alkyl" as used herein refers to an alkyl composed of 1 to 20 carbons. Examples of alkyl groups include, but are not limited to, lower alkyl groups include methyl, ethyl, propyl /-propyl, /i-buty!, /-butyl, /-butyl, pentyl, isopentyl, neopentyl hexyl heptyl, oetyl, nonyl, decyl, undecyl, dodecyl, tridecycl and hexadecyl.
The term "alkenyl" as used herein denotes an unbranched or branched chain, saturated, monovalent hydrocarbon residue of from 2 to 24 carbon atoms with a structural formula
containing at least one carbon-carbon double bond. In one embodiment, the number of carbon atoms in the alkenyl chain can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms, in another embodiment, the number of carbon atoms in the alkenyl chain can be from 5 to 1.6 and referred to as "(Cs-Cj ) alkenyl,"
When the term "alkyl" is used as a suffix following another term, as in "phenyl alkyl," or
"hydroxyalkyl," this is intended to refer to an alkyl group, as defined above, being substituted with one to two substituents selected from the other specifically-named group. Thus, for example, "phenylalkyi" denotes the radical R'R"-, wherein R' is a phenyl radical, and R" is an aikylene radical as defined herein with the understanding that the attachment point of the phenySalkyi moiety will be on the aikylene radical. Examples of arylaikyi radicals include, but are not limited to, benzyl, pheny!ethyl, 3 -phen l ropyl. The terms "arylalkyl" or "aralkyl" are interpreted similarly except R' is an aryl radical. The terms "(het)arylalkylw or "(het)aralkyl" are interpreted similarly except R' is optionally an aryl or a heteroaryl radical
The tenn "alkoxy" as used herein means an -O-alky! group, wherein alkyl is as defined above such as methoxy, ethoxy, rt-propyloxy, -propyloxy, ra-butyloxy, -hutyloxy, r-butyloxy,
pentyloxy, hexyloxy, including their isomers. "Lower alkoxy" as used herein denotes an alkoxy group with a "lower alkyl" group as previously defined. "C-rso alkoxy" as used herein refers to an-O-alkyi wherein alkyl is Cwo.
The term "halogen" as used herein means fluorine, chlorine, bromine or iodine. In one embodiment, halogen may be fluorine or bromine.
A "patient" is a mammal, e.g. , a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non- human primate, such as a monkey, chimpanzee, baboon or rhesus monkey, and the terms "patient" and "subject" are used interchangeably herein.
The term "carrier", as used in this disclosure, encompasses carriers, exeipients, and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body.
The term "treating", with regard to a subject, refers to improving at least one symptom of the subject's disorder. Treating can be curing, improving, or at least partially ameliorating the disorder.
The term "'disorder" is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
The term "administer', "administering'', or "administration" as used in this disclosure refers to either directly administering a compound or pharmaceutically acceptable salt of the compound or a composition to a subject, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.
The term "optionally substituted," as used in this disclosure, means a suitable substituent can replace a hydrogen bound to a carbon, nitrogen, or oxygen. When a substituent is oxo (i.e. , - O) the 2 hydrogens on the atom are replaced by a single O. In one embodiment, an alkyl or lower alky! group can substituted with, for example, - j, -C≡CH, phenyl or OH. It will be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are stericaliy impractical, synthetically non-feasible and/or inherently unstable. Furthermore, combinations of substituents and/or variables within any of the Formulae represented herein are permissible only if such combinations result in stable compounds or useful synthetic
intermediates wherein stable implies a reasonable pharmacologically relevant half-life at physiological conditions.
Dosage and Administration:
The compounds of the present invention may be formulated in a wide variety of oral
administration dosage forms and carriers. Oral administration can be in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions, syrups, or suspensions. Compounds of the present invention are efficacious when administered by other routes of administration including continuous {intravenous drip) topical parenteral,
intramuscular, intravenous, subcutaneous, transdermal (which may include a penetration enhancement agent), buccal, nasal, inhalation and suppository administration, among other routes of administration. The preferred manner of administration is generally oral using a convenient daily dosing regimen which can be adjusted according to the degree of affliction and the patient's response to the active ingredient.
A compound or compoimds of the present invention, as well as their pharmaceuticaliy useable salts, together with one or more conventional excipients, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions may be
employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use. A typical preparation will contain from about 5% to about 95% active compound or compounds (w/w). The term "preparation" or "dosage form" is intended to include both solid and liquid formulations of the active compound and one skilled in the art will appreciate that an active ingredient can exist in different preparations depending on the target organ or tissue and on the desired dose and pharmacokinetic parameters.
The term "excipien ' as used herein refers to a compound that is useful in preparing a pharmaceutical composition, generally safe, non-toxic and neither biologically nor otherwise
undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. The compounds of this invention can be administered alone but will generally be administered in admixture with one or more suitable pharmaceutical excipients, diluents or carriers selected with regard to the intended route of administration and standard pharmaceutical practice.
"Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither bioiogieaiiy nor otiierwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use,
A ''pharmaceutically acceptable salt" form of an active ingredient may also initially confer a desirable pharmacokinetic property on the active ingredient which were absent in the non-salt form, and may even positively affect the pharmacodynamics of the active ingredient with respect to its therapeutic activity in the body. The phrase "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1 ) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobroraic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4~hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid. 1 ,2-ethane-dis lfonic acid, 2-hydroxyethanesulfonic acid, benzenesuifonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenestdfbnic acid,
camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene- 1 -carboxylic acid, glucoheptonic acid, 3-phenylpropionk acid, trimethylaeeiie acid, tertiary butylacetic acid, lauryi sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamme, triethanolamine, tromethamine, N-methylglucamine, and the like.
Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules, A solid carrier may be one or more substances which may also act as diluents, flavoring agents, soJubiJizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material In powders, the carrier generally is finely di ided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the earner having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, meihylceiluiosc, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. Solid form preparations may contain, in addition to the active
component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizktg agents, and the like.
Liquid formulations also are suitable for oral administration include liquid formulation including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions. These include solid form preparations which are intended to be converted to liquid form preparations shortly before use. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents such as lecithin, sorbitan monooleate. or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellu!ose, sodium carboxyraethylcellulose, and other well-known suspending agents.
The compounds of the present invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, sol vents or vehicles include propylene glycol,
polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may e in powder form, obtained by aseptic isolation of sterile solid or by lyophiiization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen- free water.
The compounds of the present invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch. Ointments and. creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia o tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
The compounds of the present invention may be formulated for administration as suppositories.
A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. Tine molten
homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.
The compounds of the present invention may be formulated for vaginal administration.
Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such earners as are known in the art to be appropriate.
The compounds of the present invention may be formulated for nasal administration. The solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray. The formulations may be provided in a single or multidose form, in the latter case of a dropper or pipette, this may be achieved by the patient
administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may e achieved for example by means of a. metering atomizing spray pump.
The compounds of the present invention ma be formulated for aerosol administration,
particularly to the respiratory tract and including intranasal administration. The compound will generally have a small particle size for example of the order of five ( 5) microns or less. Such a particle size may be obtained by means known in the art, for example by micromotion. The active ingredient is provided in a pressurized pack with a suitable propellent such as a
chlorofluorocarbon (CFC), for example, dichlorodifluorome ane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas. The aerosol may conveniently al so contain a surfactant such as lecithin. The dose of drug may be controlled by a metered valve. Alternatively the active ingredients may be provided in a form of a dry powder, for exampie a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP). The powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of e. . , gelatin or blister packs from which the powder may be administered by means of an inhaler.
When desired, formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient. For example, the compounds of the present invention can be formulated in transdermal or subcutaneous drug delivery devices.
These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with a treatment regimen is crucial. Compounds in transdermal delivery systems are frequently attached to a skin-adhesive solid support. The compound of interest can also be combined with a penetration enhancer, e.g., Azone (1-dodecyiaza- eycloheptan-2-one). Sustained release delivery systems are inserted subcutaneous!}' into to the subdermal layer by surgery or injection. The subdermal implants encapsulate the compoimd in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polylaetic acid.
Suitable formulations along with pharmaceutical carriers, diluents and exeipients are described in
Remington: The Science and Practice of Pharmacy 1 95, edited by E, W. Martin, Mack
Publishing Company, 19th edition, Easton, Pennsylvania. A skilled formulation scientist may modify the formulations within the teachings of the specification to provide numerous
formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity.
The modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (salt formulation, esterification, etc.), which are well within the ordinary skill in the art. It is also well within the ordinary skill of the art to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect in patients,
The term "therapeutically effective amount" as used herein means an amount required to reduce symptoms of the disease in an individual. The dose will be adjusted to the individual requirements in each particular case. That dosage can vary within wide limits depending upon numerous factors such as the severity of the disease to be treated, the age and general health condition of the piitient, other medicaments with which the patient is being treated, the route and form of administration and the preferences and experience of the medical practitioner involved. For oral administration, a dail dosage of between about 0.01 and about 1000 mg/kg body weight pet da should be appropriate in monotherapy and/or in combination therapy. A preferred daily dosage is between about 0.1 and about; 500 nig kg body weight, more preferred 0J and about 100 mg/kg body weight, and most preferred 1 ,0 and about 15 mg/kg body weight per day. Thus, for administration to a 70 kg person, the dosage range in one embodiment would be about 70 mg to .7 g per day. The daily dosage can be administered as a single dosage or in divided dosages, typically between 1 and 5 dosages per day. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect for the individual patient is reached. One of ordinary skill in treating diseases described herein will be able, without undue
experimentation and in reliance on personal knowledge, experience and the disclosures of this
application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease and patient.
The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself" or it can be the appropriate number of any of these i packaged form.
Compounds of the present invention can be prepared beginning with commercially available starting materials and utilizing general synthetic techniques and procedures known to those skilled in the art. Chemicals may be purchased from companies such as for example
SigmaAldrieh, Argonaut Technologies, VW and Lancaster. Chromatography supplies and equipment may be purchased from such companies as for example AnaLogix, inc, Burlington, Wis.; Biotage AB, Charlottesville, Va.; Analytical Sales and Services, inc., Pompton Plains, N.J.; Teledyne Isco, Lincoln, Nebr.; VWR International, Bridgeport, N.J.; and Waters
Corporation, Milford, MA. Biotage, ISCO and Analogix columns are pre-packed silica gel columns used in standard chromatography,
EXAMPLES
The following examples further describe and demonstrate particular embodiments within the scope of the present invention. Techniques and formulations generaiiy are found in Remington ¾ Pharmaceutical Sciences {Mack Publishing Co., Eastern, Pa.). The disclosure is further illustrated by the following examples, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to
those skilled in the art without departing from the spirit of the present disclosare and/or scope of the appended claims.
Examplel
Svn thesis Protocol of E64FC26
Step 1 : l,l,l-TrifJuoro-2-hydroxy-2-(3,4-dimeih^ (1). A solution of undeean-2-one (306 mg, 1.8 mmol) in THF (8 mL) was cooled to -78 °C , then LDA (2M solution in THF, LOS mL, 2.1 mmol) was added slowly. The mixture was stirred at -78 °C for 45 mins. A solution of 2,2,2 -trifli >ro-i-(3,4-dimeihoxyplienyl)ethanone (234 mg, 1.0 mmol) in THF (2 mL) was added slowly. After stirred at -78 °C for 4 hrs, the mixture was warmed to RT for 30 mins, 20 mL of Sat'd aq. NH4CI was added. This mixture was extracted with diethyl ether (30 mL) twice. The combined ether layer was washed with brine (20 mL), dried overNa^SO.* and concentrated under vacuum. The residue was purified by ISCO flash column (0— 10% ethyl aeetate/hexanes to afford title compound 404 mg (100%). LC/MS: R - 6.88 mm, purity> 95%, (M+H - 404.68, lH NMR (300 MHz, CDCI3) S 7.13-7.22 (m, 1 H), 6.91-7.05 (m, lH), 6,83 (d, J=8.50 Hz, 1H), 3.85 (s, 3H), 3.86 (s, 3H), 3.05-3.36 (m, 2H), 2.28-2.58 (m, 2H), 1.40-1.61 (m, 21 ! k 1.22 (br. s., ! 2H), 0.86 (ί, Λ=6.45 l . 3H)
Step 2: (^-S-CTdfluoronieth -S^dimethoxy-l-non lid ne-lH-indeiie (2) and (E)~3- (tiiJ aoromethyI)-$,6-di.met ox -l-»oitylideR -ll{ ndene 0) The mixture of I (202 rag, 0,5 mmol), TsOH (48 mg, 0.25 mmol) in toluene (3 mL) was heated at 100 l,C for 5 hrs. After reaction was done, the mixture was concentrated. The residue was purified by ISCO eluting with 0— 10% ethyl acetate/ hexanes to give the isomers (2: 34 mg; 3: 1.38 mg). LC/M.S: i½ - 8.42 rain, purity> 95%, (M+Hfc* = 369.66. {H NMR (300 MHz, CDCI3) δ 7.29-7.40 (m, IH), 6.96- 7.04 (m, IH), 6.72 (s, IH), 6.41 -6.60 (m, IH), 3.92-4,03 (m, 6H), 2.73-2.92 (ra, 2H), 1.58-1.81 (m, 2H), 1 .24-1.56 (m, 10H), 0.77-1.02 (m, 3H); Re » 8.27 mm, purity> 95%, (M+H - 369,66. 1H NMR (300 MHz, CDCI3) δ 7.14-7.26 (m, 1 H), 7.07 (br. s., 1 1), 6.98 (s, 1 1), 6.81, (t, J-7.91 Hz, 1.H), 3.93-4.05 fro, 6H), 2.60 (q, J-7.42 Hz, 2H), 1.51 -1.72 (m, 2H), 1.20-1.50 (m, lOH), 0.76-1.07 (m, 3H)
Step 3- 1 : (i¾-3-{Tritluoromethyl)-l-nonyMdene-lH-indene-5,6-dioi (FC-7947). To a solution of in 2 (41 mg, 0.11 mmol) in C¾t¾ (1 mL) was added 0.33 mL 1 M BBn solution in CH2CI2 at ~78"C and stayed, at -78 "C for 1 hr. The mixture was then warmed up to -20 °C for 1.5 hrs.
TLC indicated the reaction was done. 4 mL NH4C1 and 5.0 mL ether were added. The organic layer was separated, dried, concentrated. The residue was purified to give FC-7947 (25 mg, 67% yield). LC/MS: Rf === 6.93 min. purity >95%,. (M+H)+ - 341,64. JH NMR (300 MHz, CDCI3) δ 7.32-7.50 (m, I H), 6,94-7.13 (m, IH), 6.61 -6.81 (m, I H), 6.38-6.60 (m. 1H), 5.25-5.68 (m, 2H), 2.54-2.85 (m, 2H), 1.56-1.79 (m, 2H), 1. 17- 1.52 (m, 1.0H), 0.76- 1 .04 (m, 311)
Step 3-2: (£)-3-(l>ii]uoromethyl)-l~nonylidene-lH-ludene-5,6-diot (FC-7362), To a solution of 3 (158 mg, 0.43 mmol) m CH2CI2 (5 raL) was added 1.3 mL 1M BB¾ solution in CH2CI2 at - 78°C and stirred at -78 °C for lhr. The mixture was then warmed up to -20 °C tor 1.5 hrs. TLC indicated the reaction was done. 15 mL NH4CI and 30 mL ether were added. The organic layer was separated, dried, concentrated. The residue was purified by ISCO to give FC-7947 (96 mg, 65% yield). LC/MS: f - 6.93 min, purity >95%, (M+Hf - 341.64. Ή NMR (300 MHz,
CDCI3) δ 7.10-7.23 (m, 1 Εί), 7.00-7.09 (m, 1.H), 6.98 <d, J=== 1.17 Hz, 1H), 6.62-6.77 (m, 1H), 2.46-2.65 (m, 2H), 1 ,46- 1.68 (in, 2H)S 1.20-1.45 (m, 10H), 0,79-1 ,02 (in, 3H).
Example 2
Synthesis Protocol of E64FC65
Step 1 : 2~(benz0[d| (1,3 jdioxol«6~yl)~l *iriflttoro-2-hydr0x undecai-«4«one (4). A soiution of nonan-2-one (983 mg, 6.9 mmoi) in THF (50 mL) was cooled to -78 "C, and then LDA (2M solution jii THF, 4.0 mL, 7.8 mmoi) was added slowly. The mixture was stirred at -78 °C for 45 mins. A solution of l-( enzo[d][1 ]dioxol-6-yi)-2,2i2-trifltioiO ethanone (1.0 g, 4.6 mmoi) in THF (5 mL) was added slowly. After stirred at -78 °C for 4 hrs, the mixture was warmed to T for 30 mins, 100 mL of Sat'd aq. NH4CI was added. This mixture was extracted with diethyl ether (100 mL) twice. The combined ether layer was washed with brine (50 mL), dried over Na2$0 and concentrated under vacuum. The residue was purified by ISCO flash column (0— 10% ethyl acetate hexanes to afford title compound 1.62 g (98%). LC/MS: Rf = 6.70 mm, purity> 95%, (M)+ = 360. 1.
Step 2; (5Z)-7>(tnl1uoromethyI)-5-heptyIldene-5H-indeno[S,6^Hi Idioxoie (FC-9377) and
(5E)-7-(trif1uoromethyl)-5-heptylki .ene-5H-tnd eno [5,6-d ] [ 1 ,3] diox le (FC-8975, E64FC65)
The mixture of 4 ( L62 g. 4.5 mmoi), TsOH (387 mg, 2.25 mmoi) in toluene (25 ml) was heated at .125 °C for 1.5 hrs. After reaction was done, the mixture was concentrated. The residue was purified by ISCO elating with 0— 10% ethyl acetate/ hexanes to give the mixture (557 mg). This mixture was further purified by Giison (75— 100% MeCN/S¾0) to give the title compounds
(FC-8975, 288 mg) and (FC-9377, 1.4 mg). LC/MS: R.« - 7.86 min, purity> 95%, (M+H)i+ -
325.59. 'Ή NMR (300 MHz, CD ¾) 5 7.04-7.14 (m, 2H), 7,01-7,07 (in, 111), 6.86-6.99 (ra, 1 H), 6.65-6.82 (m, IH), 5,99 (s, 2H), 2,46-2,68 (m, 2H)S 1.47-1.70 (m, 2H), 1.17-1 ,46 (m, 7H), 0.79- 0.99 (m, 3H)
f2 - 7,94 min, purity> 95%, (M = 324.64. 1H NMR (300 MHz, CDC¾) δ 7.09 (s, IH), 6.94 (s, I H), 6.68-6.69 (m, IH), 6.49 (t, J-7.32 Hz, ί H), 6.00 (s, 2H), 2.70 (q, 2H), 1.59-1.66 (m, 2H)? L30-L35 (m, 6H), 0.87-0.92 (m, 3H)
Example 3
Synthesis Protocol of Additional Compounds of the Invention
Using the procedures in Examples 1 and 2 above, the ioilowing compounds were also be prepared:
9
Example 4
Biological Assays
Pr teasome ^ Inhibitor 111 sensitizing 111 char ct ris ties 111 of 111 representative 111 eo po u ads 111 o ι L he invention
Reference is made to Figure 1 , (A) The structures of novel derivatives E64FC26 and E64FC65 are shown, (B) Proteasome inhibitor (PI) resistant MM. I S BzR cells were treated with the E64FC26 at a concentration of 500 nM and a dose range of the ΡΪ boriezomib (Btz). Cell viability was measured after 24 hours of treatment. The calculated. Btz EC 50 for control cells treated with the DMSO vehicle was 45.5 nM compared to and EC50 of 4.7 nM in cells co-treated with E64FC26, a 9.7-fold increase in Btz sensitivity. (C) PANC-l pancreatic cancer cells were treated with the indicated derivative at a final concentration of 1 μΜ and a dose range of Btz. Cell viability was measured after a 48 hour treatment time. The Btz EC50 in the presence of DMSO vehicle control was 83.5 nM compared to 9.1 nM in the presence of E64FC26 and 1.8 nM in the presence of E64FC65, corresponding to a 9.2-fold and 46.4-fokl increase in Btz sensitivity, respectively. (D) Panels of pancreatic, ovarian, glioma, multiple myeloma, and normal cells were treated with E64FC26 and a dose range of the second generation proteasome inhibitor earfitzomib (Crflz) using a protocol similar to th i described above for panels (B) and (C). Crflz EC50 values were extrapolated from dose curves conducted in the presence and absence of E64FC26 and a fold-change was calculated. Each data point represents the fold- change, or the degree of Crflz potentiation, for each cell line tested..
Broad spectrum single agent anti-tumor efficacy of representative coropo imds o the invention
Reference is made to Figure 2. Cell lines originating from the indicated tumor types were treated with 1 uM E64FC26. After 48 hours of treatment ceil viability was measured. Data represent the % viable cells relative to DMSO treated control cell cultures.
HDAC I n hibitor sensitizing charge terisdcs of representative compo a nds of the, in y entipn
Reference is made to Figure 3. (A) In PA C-l pancreatic cancer cells, the cytotoxicity of each of the indicated HDAC inhibitors was evaluated in the presence and absence of I μΜ E64FC26. EC50 values are shown. (B) Similar experiments as described in (A) were conducted using T98G glioblastoma cells. EC50 values for each of the HDAC inhibitor in the presence and absence of 1 μ E64FC26. (C) Panels of the indicated tumor cell types were treated with a dose range of the HDAC inhibitor panobinostat in the presence and absence of 1 μΜ E64FC26. EC50 values were extrapolated and the relative effect of E64FC26 on panobinostat sensitivity was calculated. Each data point indicated the fold change in panobinostat EC50 for that particular cell line. (D) An example of Ml panobinostat dose response curves in PANC-l pancreatic cancer cells are shown. PANC-l cells were co-treated with DMSO vehicle control, 1 μΜ E64FC26, or ί μΜ E64FC65. The panobinostat EC50 in DMSO treated cells was 453 nM compared to 5.3 nM in the presence of E64FC26 and 1.1 nM in the presence of E64FC65, an increase in panobinostat sensitivity of 85.5-fold and 412-fold, respectively.
In viva anti-MM activity of E64FC26
Reference is made to Figure 4. The weekly dosing schedules for E64FC26 (2 mg/kg, i,p.) and Biz (0.25 mg/kg, i.p.) are shown. (B) NSG mice were injected i.v. with 1 x 106 arental MM. IS cells. After 7 days, mice were randomized into groups (N=8-9) that received treatment with vehicle, E64FC26, Biz, or the combination of E64FC26/Btz using the dosing regimen outlined in Survival data are shown.
I nhibition of PI) I activity by representative compounds of the invention in vitro
Reference is made to the data table in Figure 5. The table provides the following data for each of the indicated derivatives:
1. EC50 values in cytotoxicity assays in proteasome inhibitor resistant M cells (MM. I S BzR) as a single agent [column labeled (-) Bt/j.
2. EC50 values in cytotoxicity assays in proteasome inhibitor resistant MM cells (MM, IS BzR) in combination with 20 nM Biz [column labeled (+-) 20 nM Btz],
3. PDI inhibition JC50 in in vitro PDI assays. PDI biochemical assays were performed by incubating 1 μΜ of recombinant purified PDI for ί hour at 37 degrees Celsius. 100 μΜ human insulin and 1 mM DTT were added to initiate the PDI catalyzed aggregation of insulin. The absorbance changes at 650 nm were followed, over 45 miniiies with measurements taken every minute. The absorbance values in the exponential range were taken and normalized to PDI activity in the absence of inhibitor.
The invention is further described in the following numbered paragraphs:
1. A compound of formula (I):
where n: { and 1¾* independently of each other, are hydrogen, hydroxy!, alky], alkoxy, methoxy-aeetate, phosphate, valine, Gly-Ser, -OC(Q)CH2OC(Q)CH3, "OC(0)CH2OC¾, -OCH2C(0)C(C¾)3f - OC¾C(0)NH2 or -QCH2C(0)OH; or R} and R?, together with the carbon atoms to which ihey are attached, form a 5 to ό-nieinbered ring with one or two ring carbons replaced independently by oxygen or nitrogen;
Rs is hydrogen, hydroxy!, halogen, cyano. -COOH, -CiO)NH2, -C(0)C¾CI¾, -C(0)-alkoxy, alky], alkoxy, halo-lower alky 1 , earhoxyl, amide, ester or nitrite; and
R.4 Is alky! or alkenyl, said alky! or alkenyl optionally mono or bi-substituted independently with hydrogen, halogen, hydroxy!, -OCHj-phenyl, cycloalkyl, X¾-halophenyi or -OC¾- pbenylha!oaikyl, or a pharmaceuticaliy acceptable salt thereof.
2. The compound according to paragraph ί , wherein Rt and R2, independently of each other, are hydrogen, hydroxy!, alkyl, alkoxy, methoxy-acetaie, phosphate, valine. Gly-Ser. - OC(0)C¾OC(0)CH3, -OC(0)CH2QCH3, ~OCB2CfO)C(CH )3, ~OCH2C(0)NH2 or - QCi¾C(0)OB.
3. The compound according to paragraph 1, wherein Ri and Ra, together wi th the carbon atoms to which they are attached, form a 5 to 6-membered ring with one or two ring carbons replaced independently by oxygen or nitrogen,
4. The compound according to paragraph 1 , wherein Rj is hydroxy!.
5. The compound according to paragraph 1 , wherein R2 is hydroxy!.
6. The compound according to paragraph 1 , wherein both j and _¾ are hydroxy!.
7. The compound according to paragraph J , wherein Rj is alkoxy.
8. The compound according to paragraph 1 , wherein R:j is alkoxy.
9. The compound according to paragraph 1 , wherein both R} and R; are alkoxy,
10. The compound according to paragraph 1, wherein R3 is hydrogen, hydroxy!, halogen, cyano, -COOH, -C(0)NH2, .C(0)CH2CH3, -C(0)~alkoxy, alkyl, alkoxy, halo-lower alkyl, carboxyt, amide, ester or nitrile.
1 1. The compound according to paragraph t , wherein R3 is amide.
12. The compound according to paragraph 1 , wherein R? is -CF3.
13. The compound according to paragraph I , wherein R4 is alkenyl.
14. The compound according to paragraph 1. wherein ¾ is a!kenyl optionally mono or hi- substituted independently with hydrogen, halogen, hydroxy!, -OCHa-phenyl, cycloalkyl, -OCH halophen I or OC !¾~phenylhaloa]ky i .
15. A compound, wherein said compound is:
rmaceutically acceptable salt thereof.
16. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to paragraph 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
17. A method for the treatment of cancer, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to paragraph 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
18. A method for the treatment of multiple myeloma, comprising the step of administering to a patient in need thereof a therapeutically effective amo unt of a compound according to paragraph i, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
1 . A method for enhancing the activity of proteasome and/or HDAC inhibitors, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to paragraph 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
20. A method for enhancing the activity of proteasome and/or HDAC inhibitors during treatment of multiple myeloma, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to paragraph 1 , or a
pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
21. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to paragraph 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
22. A method for the treatment of cancer, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to paragraph ! 5S or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
23. A method for the treatment of .multiple myeloma, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to paragraph 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
24. A method for enhancing the activity of proteasome and/or HDAC inhibitors, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to paragraph 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier,
25. A method for enhancing the activity of proteasome and/or HDAC inhibitors during treatment of multiple myeloma, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to paragraph 13, or a
pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
S?
It is to be understood that tlie invention is not limited to the particular embodiments of tlie invention described above, as variations of the particular embodiments may be made and still fall within the scope of the appended claims.
Claims (1)
- CLAIMS:1. A compound of formula (]);wherein: i and R2, independently of each other, are hydrogen, hydroxy}, a!kyl, alkoxy, meihoxy-aeetate, phosphate, valine, G!y-Ser, -OC(0)CH2OC(0)C¾, ~OC(0}CH2OC¾ -OCH2C(0)C(CH3) i - OCi¾C(0)NH2 or - CH C(0)OM; or Rj and R2, together with the carbon atoms to which they are attached, form a 5 to 6-membered ring with one or two ring carbons replaced independently by oxygen or nitrogen; .i is hydrogen, hydroxyl, halogen, cyano, -COOH, -C(0)N¾? (0)C¾Cr¾, ~C(0)-alkoxy, alkyl, alkoxy, halo-lower alky I, earboxyl, amide, ester or niirite; andRi) is alkyl or aikenyt, said alkyl or aikenyl optionally mon o bi~substituted independently with hydrogen, halogen, hydroxy!, -OCH?-phenyL cycloalkyl -OCHi-halophenyl or ~OCH2~ pheny !haloalky I , or a pharmaceutically acceptable salt thereof.2, The compound according to claim 1, wherei R¾ and R2} independently of each other, are hydrogen, hydroxy!, alky], alkoxy, methoxy-acetate, phosphate, valine, Gly-Ser, - 0C(O)t¾OC(O)C¾, -OC(0)CH2OCH3, -OCH2C(0)C(CH3)3, -OCH2C(0)NH2 or ~OCH2C(0)OH.3. The compound according to claim 1, wherein Rj and !¾, together with the carbon atoms to which they are attached, form a 5 to ό-membered ring with one or two ring carbons replaced independently by oxygen or nitrogen.4. The compound according to claim .1 , wherein Rj is hydroxyl.5. The compound according to claim 1 , wherein j is hydroxyl.6. The compound according to claim 1 , wherein both Rj and R2 are hydroxyl.7. The compound according to claim .1 , wherein R^ is aikoxy.8. The compound according to claim 1 , wherein R2 is aikoxy.9. The compound according to claim 3 , wherein both R{ and j are aikoxy,10. The compound according to claim 1 , wherein R3 is hydrogen, hydroxyl , halogen, cyano, - COOH, -C(<))NH2, -C(0)C¾CH3, -C(0)-aIkoxy, alkyl, aikoxy, halo-lower alkyl, carboxyl, amide, ester or nifrile.I I , The compound according to claim 1, wherein 3 is amide. 32, The compound according to claim 1, wherein R3 is -CF3.13. The compound according to claim 1 , wherein R is alkenvl.14. The compound according to claim 1 , wherein R4 is alkenyl optionally mono or bi- substituted independently with hydrogen, halogen, hydroxyl, -OCl¾~phenyl, cycloalkyl. -QCH halophenyl or OO -phefryilialoalkyl.15. A compound, wherein said compound is:rmaceutically acceptable salt thereof.16. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim I , or a pharmaceutically acceptable salt thereof and apharmaceutically acceptable earner,17. A method for the treatment of cancer, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim I, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.18. A method for the treatment of multiple myeloma, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt ihereof and a pharmaceutically acceptable carrier,1 . A method for enhancing the activity of proteasome and/or HDAC inhibitors, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and apharmaceutically acceptable carrier.20. A method for enhancing the activity of proteasome and/or HDAC inhibitors during treatment of multiple myeloma, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.21. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 15, or a pharmaceutically acceptable salt thereof and apharmaceutically acceptable carrier.22. A method for the treatment of cancer, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.23. A method for the treatment of .multiple myeloma, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 15. or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.24. A method for enhancing the activity of proteasome and/or HDAC inhibitors, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.25. A method for enhancing the activity of proteasome and/or HDAC inhibitors during treatment of multiple myeloma, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 15, or a pharmaceutically acceptable salt thereof and a phamiacetitica!!y acceptable carrier.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762552449P | 2017-08-31 | 2017-08-31 | |
US62/552,449 | 2017-08-31 | ||
PCT/US2018/048449 WO2019046368A1 (en) | 2017-08-31 | 2018-08-29 | Indene derivatives and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2018323528A1 AU2018323528A1 (en) | 2020-02-06 |
AU2018323528B2 true AU2018323528B2 (en) | 2023-01-12 |
Family
ID=65434074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2018323528A Active AU2018323528B2 (en) | 2017-08-31 | 2018-08-29 | Indene derivatives and uses thereof |
Country Status (7)
Country | Link |
---|---|
US (2) | US10329269B2 (en) |
EP (1) | EP3676242B1 (en) |
JP (1) | JP7330168B2 (en) |
CN (1) | CN111148732A (en) |
AU (1) | AU2018323528B2 (en) |
CA (1) | CA3072616A1 (en) |
WO (1) | WO2019046368A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111148732A (en) * | 2017-08-31 | 2020-05-12 | Musc研究发展基金会 | Indene derivatives and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4568782A (en) * | 1985-06-17 | 1986-02-04 | The Standard Oil Company | Preparation of indenes |
EP2647622A1 (en) * | 2010-12-03 | 2013-10-09 | Fujitsu Limited | Novel compound, and kinesin spindle protein inhibitor and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2592365A (en) * | 1944-03-02 | 1952-04-08 | Polymerisable Products Ltd | Condensation process |
WO1998030567A1 (en) | 1997-01-14 | 1998-07-16 | Sumitomo Chemical Company, Limited | Process for producing cyclopentadienyl metal salts and process for producing cyclopentadiene derivatives by utilizing the same |
WO2005073264A1 (en) | 2004-01-30 | 2005-08-11 | Nippon Steel Chemical Co., Ltd. | Curable resin composition |
JP5197014B2 (en) | 2004-12-10 | 2013-05-15 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | Heterocyclic derivatives as histone deacetylase (HDAC) inhibitors |
WO2014205380A1 (en) | 2013-06-21 | 2014-12-24 | Beth Israel Deaconess Medical Center, Inc. | Compounds and compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase |
US9359342B2 (en) | 2013-11-08 | 2016-06-07 | The Cleveland Clinic Foundation | Protein disulfide isomerase inhibiting anticancer agents |
US20160168108A1 (en) * | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
US9862698B2 (en) | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
WO2016118639A1 (en) | 2015-01-20 | 2016-07-28 | The Trustees Of Columbia University In The City Of New York | Small molecule oxidizers of pdi and their use |
CN111148732A (en) * | 2017-08-31 | 2020-05-12 | Musc研究发展基金会 | Indene derivatives and use thereof |
-
2018
- 2018-08-29 CN CN201880056346.XA patent/CN111148732A/en active Pending
- 2018-08-29 EP EP18850996.2A patent/EP3676242B1/en active Active
- 2018-08-29 CA CA3072616A patent/CA3072616A1/en active Pending
- 2018-08-29 AU AU2018323528A patent/AU2018323528B2/en active Active
- 2018-08-29 US US16/115,780 patent/US10329269B2/en active Active
- 2018-08-29 JP JP2020509439A patent/JP7330168B2/en active Active
- 2018-08-29 WO PCT/US2018/048449 patent/WO2019046368A1/en unknown
- 2018-08-29 US US16/633,464 patent/US11731952B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4568782A (en) * | 1985-06-17 | 1986-02-04 | The Standard Oil Company | Preparation of indenes |
EP2647622A1 (en) * | 2010-12-03 | 2013-10-09 | Fujitsu Limited | Novel compound, and kinesin spindle protein inhibitor and application thereof |
Non-Patent Citations (12)
Title |
---|
ALT, HG. et al. J. Organometallic Chem., 2001, 628, 169-182 * |
BOREUX, A. ET AL: ORGANIC LETTERS, vol. 18, no. 19, 2016, pages 5162 - 5165 * |
de ARMAS, J. et al. J. Am. Chem. Soc., 2000, 122, 5977-5983 * |
DEPPNER M ET AL: J. Organometallic Chem., 2004, 689, 1194-1211 * |
DONSLUND, BS. Et al. Angewandte Chemie International Edition, 2016, 55, 11124-11128 * |
MAHENDAR L. ET AL: JOURNAL OF ORGANIC CHEMISTRY, vol. 79, no. 5, 2014, pages 2059 - 2074 * |
MAZZOCCHI, P. H. ET AL: JOURNAL OF MEDICINAL CHEMISTRY, vol. 24, no. 4, 1981, pages 457 - 462 * |
ODEDRA, A. ET AL: JOURNAL OF ORGANIC CHEMISTRY, vol. 72, 2007, pages 3289 - 3292 * |
PANARELLO, AP. Et al. Tetrahedron Letts., 2005, 46, 1353-1356 * |
POLO-CERON, D. et al. Polyhedron, 2014, 80, 129-133 * |
SPENCER, T. A. ET AL: TETRAHEDRON, vol. 66, no. 25, 2010, pages 4441 - 4451 * |
SUGIE, A. et al. Tetrahedron Letts., 32, 2759-2762 * |
Also Published As
Publication number | Publication date |
---|---|
CN111148732A (en) | 2020-05-12 |
JP7330168B2 (en) | 2023-08-21 |
EP3676242A1 (en) | 2020-07-08 |
EP3676242B1 (en) | 2024-03-06 |
JP2020532502A (en) | 2020-11-12 |
US11731952B2 (en) | 2023-08-22 |
EP3676242A4 (en) | 2021-04-21 |
US20200165182A1 (en) | 2020-05-28 |
US20190062298A1 (en) | 2019-02-28 |
US10329269B2 (en) | 2019-06-25 |
AU2018323528A1 (en) | 2020-02-06 |
WO2019046368A1 (en) | 2019-03-07 |
CA3072616A1 (en) | 2019-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2013326486B2 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
US11434205B2 (en) | Substituted imidazole carboxylate derivatives and the use thereof | |
JP6905597B2 (en) | N-substituted imidazole carboxylic acid ester compound and its preparation method and application | |
EP1382333B1 (en) | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | |
CN111662294A (en) | Compound with activity of degrading Btk | |
AU2018323528B2 (en) | Indene derivatives and uses thereof | |
EP3992185A1 (en) | Hydrazone amide derivative and application thereof in preparation of medicaments for preventing and treating alopecia | |
EP3992184A1 (en) | Hydrazone amide derivatives and use thereof in preparation of anti-osteoporosis drugs | |
US10392354B2 (en) | Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer | |
CN108558760B (en) | Aromatic amide compounds, preparation method and application thereof | |
EP4043440A1 (en) | Substituted nitrogen heterocyclic compound and anesthetic effect thereof | |
CN111574582B (en) | Tripterine derivative and preparation method and application thereof | |
EP3560914A1 (en) | Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof | |
JPH0640989A (en) | New compound | |
CN115141169B (en) | Terpene lactone derivative and application thereof in medicine | |
CN114478494B (en) | Derivatives of nitroimidazole compounds, pharmaceutical composition, preparation method and application thereof | |
JPS63501870A (en) | New propane-1,3-diol derivatives and their uses | |
CZ286781B6 (en) | Pharmaceutical preparation for treating cancer and diseases caused by abnormally increased cell proliferation | |
WO2017161093A1 (en) | Caffeic acid derivatives and uses thereof | |
EP1980562A1 (en) | Taxol derivatives with antitumor activity | |
CN117777093A (en) | Small molecule compound for preparing GnRH1R agonist | |
KR101458494B1 (en) | New arylsulfonylimidazolone derivatives and an anti-cancer pharmaceutical composition comprising the same | |
JP2003183205A (en) | New substance having antitumor and antiinflammatory action | |
FR2855520A1 (en) | New 2-phenoxymethyl-4-phenyl-imidazole derivatives, useful particularly as antitumor agents, act by inhibiting polymerization of tubulin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |